Ionis Pharmaceuticals (IONS) Interest & Investment Income (2009 - 2026)

Ionis Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at $20.2 million for Q2 2026.

• In Q2 2026, Interest & Investment Income fell 18.05% year-over-year to $20.2 million; the TTM figure through Jun 2026 stood at $94.1 million (down 9.92% YoY), while the FY2025 annual figure was $97.8 million, down 8.65% from the prior year.
• Interest & Investment Income for Q2 2026 stood at $20.2 million, down from $25.5 million in the prior quarter.
• The five-year high for Interest & Investment Income was $28.9 million in Q4 2024, with the low at $2.0 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $24.3 million (2023), against an average of $20.2 million.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income sank 57.08% in 2022, then surged 834.62% in 2023.
• Ionis Pharmaceuticals' Interest & Investment Income stood at $11.9 million in 2022, then surged by 116.14% to $25.7 million in 2023, then gained by 12.55% to $28.9 million in 2024, then declined by 14.46% to $24.7 million in 2025, then fell by 18.2% to $20.2 million in 2026.
• Business Quant data shows IONS's Interest & Investment Income at $20.2 million in Q2 2026, $25.5 million in Q1 2026, and $24.7 million in Q4 2025.